WHO Suspendes Hydroxychloroquine Trials Pending Safety Data

The Solidarity trial aims to assess the safety and efficacy of treatments for COVID-19, involving over 400 hospitals across 75 countries. A recent study published in The Lancet highlighted concerns about Hydroxychloroquine, prompting a temporary pause in its trial arm for safety review. The trial's executive group is conducting a comprehensive analysis of global data to evaluate the drug's risks and benefits. While Hydroxychloroquine is generally safe for autoimmune diseases and malaria, its use in COVID-19 is under scrutiny. WHO will provide updates as more information becomes available.

What was the purpose of initiating the Solidarity trial?

Evaluate responses using AI:

OFF

What were the findings of the observational study published in The Lancet regarding Hydroxychloroquine and Chloroquine?

Evaluate responses using AI:

OFF

What will the review by the executive group consider in terms of data?

Evaluate responses using AI:

OFF

What actions did the executive group of the Solidarity trial take regarding the Hydroxychloroquine arm?

Evaluate responses using AI:

OFF

What is the general safety status of Hydroxychloroquine and Chloroquine for patients with autoimmune diseases or malaria?

Evaluate responses using AI:

OFF